Cardiac Damage Analysis
Cardiac Damage Analysis - Related Videos
06:38
Simultaneous 3D Analysis of Cardiac Damage and Immune Response in Reperfused Acute Myocardial Infarction Using Light Sheet Fluorescence Microscopy
0 Views •
2025
Three-dimensional (3D) reconstruction of cardiac damage in reperfused acute myocardial infarction (repAMI) enables faithful quantification and co-localization of associated disease-affecting patterns. Here, an automatable light sheet-guided imaging approach is provided for contemporaneous measurement of cardiac damage, area at risk, and immune cell response.
08:15
Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
0 Views •
Cited by 33 •
2015
Cardiac pressure-volume loop analysis is the most comprehensive way to measure cardiac function in the intact heart. We describe a technique to perform and analyze cardiac pressure volume loops, using conductance catheters.
11:49
Analysis of the Epithelial Damage Produced by Entamoeba histolytica Infection
0 Views •
Cited by 5 •
2014
Human infection by Entamoeba histolytica leads to amoebiasis, a major cause of diarrhea in tropical countries. Infection is initiated by pathogen interactions with intestinal epithelial cells, provoking the opening of cell-cell contacts and consequently diarrhea, sometimes followed by liver infection. This article provides a model to assess the early host-pathogen interactions to improve our understanding of amoebiasis pathogenesis.
07:32
Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes
0 Views •
Cited by 2 •
2022
A set of protocols are presented that describe the measurement of contractile function via sarcomere length detection along with calcium (Ca2+) transient measurement in isolated rat myocytes. The application of this approach for studies in animal models of heart failure is also included.
08:25
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
0 Views •
Cited by 11 •
2015
Streptococcus pneumoniae forms discrete non-purulent microscopic lesions in the heart. Outlined is the protocol for a murine model of cardiac microlesion formation. Instruction is provided on microlesion visualization using microscopy, discrimination between early and late microlesions, and methods to detect cardiac remodeling in hearts of convalescent animals.
FAQs
The assessment separates evidence of tissue injury from evidence that the heart is functioning abnormally. Cardiac biomarkers indicate injury to myocardial cells, whereas electrocardiography and imaging can reveal ischemia, impaired contraction, or structural abnormalities. Considering these findings together helps clinicians determine whether an observed functional change reflects damage and supports more informed diagnosis and risk assessment.
Each measurement addresses a different aspect of cardiac abnormality. Biomarkers provide evidence of myocardial-cell injury, electrocardiography evaluates electrical patterns associated with ischemia or other changes, and echocardiography or other imaging methods show contraction and structure. Their combined use creates a more complete assessment than relying on a single measurement, particularly when structural, electrical, and cellular findings do not fully overlap.
Serial assessments show whether cardiac abnormalities are progressing, stabilizing, or improving. Comparing measurements over time can track disease evolution or recovery rather than capturing only one moment. This temporal information may strengthen risk assessment, support timely intervention, and help clinicians evaluate changes associated with conditions such as myocardial infarction, myocarditis, heart failure, or treatment-related cardiotoxicity.
The process begins with clinical findings and then incorporates appropriate measurements of myocardial injury, electrical activity, cardiac function, and structure. Biomarker results can be interpreted alongside electrocardiography and echocardiography or other imaging findings. Repeating selected assessments when clinically relevant allows comparison over time, helping identify progression or recovery and supporting diagnostic and management decisions.
Clinicians apply cardiac damage analysis when evaluating suspected myocardial infarction, myocarditis, heart failure, or treatment-related cardiotoxicity. The findings help distinguish tissue injury from changes in normal function, estimate risk, and identify patterns that may require timely attention. Because the approach combines several forms of evidence, it can be adapted to different clinical questions rather than serving only one diagnosis.
Standardized analysis gives researchers comparable measures of injury, electrical change, impaired contraction, and structural abnormality. Repeated measurements can document disease progression or recovery, while integrated findings help examine disease mechanisms and evaluate therapies. Applying consistent assessment methods also improves the study of patient outcomes across conditions such as myocardial infarction, myocarditis, heart failure, and cardiotoxicity.